[Management of patients with left main stem stenosis in Iceland 2010-2020: PCI or CABG]

Heidrun Osk Reynisdottir1, Margret Kristin Kristjansdottir1, Brynjolfur Arni Mogensen2

  • 1Faculty of Medicine, University of Iceland.

Laeknabladid
|August 30, 2022
PubMed

Insights

Percutaneous coronary intervention (PCI) is increasingly used for left main coronary artery disease (LMCAD) treatment in Iceland, with factors like age and disease complexity influencing choice. Long-term survival shows no significant difference between PCI and coronary artery bypass surgery (CABG).

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Health Services Research

Background:

  • Coronary artery bypass surgery (CABG) is the traditional treatment for left main coronary artery disease (LMCAD).
  • Percutaneous coronary intervention (PCI) offers a viable alternative for LMCAD revascularization.
  • Understanding treatment trends and outcomes in LMCAD is crucial for patient care.

Purpose of the Study:

  • To evaluate revascularization strategies for LMCAD patients in Iceland.
  • To analyze changes in LMCAD treatment over recent years.
  • To assess the impact of patient factors on treatment selection and long-term survival.

Main Methods:

  • Retrospective population-based registry study using the SCAAR-SWEDEHEART database.
  • Inclusion of LMCAD patients undergoing coronary angiography in Iceland (2010-2020).
  • Kaplan-Meier and COX-regression analyses for survival and predictor variables.

Main Results:

  • PCI use for LMCAD increased from 19.8% (2010-2015) to 42.7% (2016-2020).
  • Treatment choice was influenced by patient age, anatomical complexity (three-vessel disease, valve disease), and acuteness (STEMI, cardiogenic shock).
  • No significant difference in long-term survival was observed between PCI and CABG groups (p=0.41).

Conclusions:

  • Age, anatomical complexity, and acuteness are key determinants for LMCAD treatment selection.
  • A notable rise in PCI utilization for LMCAD patients has been observed.
  • PCI and CABG demonstrate comparable long-term survival rates in LMCAD patients.
Abstract

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
22
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
18
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
24
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
29
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
17
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
38